These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31008763)

  • 41. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.
    Eftekhar SP; Yazdanpanah N; Rezaei N
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1211-1228. PubMed ID: 34511008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
    Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
    Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
    Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS).
    Wang Q; Xiao F; Zeng Y; Zhu Q; Zhang H
    Expert Opin Drug Saf; 2024 Feb; 23(2):257-267. PubMed ID: 37070426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
    Renna CE; Dow EN; Bergsbaken JJ; Leal TA
    J Oncol Pharm Pract; 2019 Jun; 25(4):954-960. PubMed ID: 30975067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment and Management of Cardiotoxicity in Hematologic Malignancies.
    Bojan A; Torok-Vistai T; Parvu A
    Dis Markers; 2021; 2021():6616265. PubMed ID: 33613788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardio-oncology: the new frontier of clinical and preventive cardiology.
    Paris S; Tarantini L; Navazio A; Faggiano P
    Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
    Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
    Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.